Sublingual, Buccal, and ODT: The Science Behind Non-Injectable GLP-1 Delivery
Key Takeaways
- Sublingual (under the tongue), buccal (between cheek and gum), and ODT (orally disintegrating tablet) are three distinct non-injectable delivery methods
- Each bypasses the stomach to varying degrees, avoiding the GI degradation problem that makes oral peptide delivery difficult
- Sublingual absorption enters the bloodstream through mucous membranes — faster onset, but absorption rates vary
- None of these formats have FDA-approved GLP-1 products — they exist only in the compounded space
- The SNAC technology in oral Wegovy/Rybelsus is a different approach: stomach absorption with a protective enhancer
If you've looked into non-injectable GLP-1 options beyond standard pills, you've probably encountered sublingual drops, buccal troches, and ODT tablets. These aren't just different shapes — they use fundamentally different absorption pathways than the pills you'd pick up at a pharmacy. Here's the science behind each format.
The Core Problem: Peptides Don't Survive the Stomach
Semaglutide and tirzepatide are peptides — chains of amino acids. When you swallow a peptide, stomach acid and digestive enzymes break it apart before most of it can reach your bloodstream. The oral bioavailability of unprotected semaglutide is estimated at roughly 1% — meaning 99% of what you swallow gets destroyed.
FDA-approved oral semaglutide (Wegovy pill, Rybelsus) solves this with SNAC (sodium salcaprozate), a chemical that temporarily raises the pH around the tablet and enhances absorption through the stomach lining. It works, but it requires the 30-minute empty-stomach protocol to function properly.
Sublingual, buccal, and ODT formats take a completely different approach: they try to get the peptide into your bloodstream before it reaches the stomach.
Sublingual Delivery
Sublingual means "under the tongue." A liquid drop or dissolving tablet is placed under the tongue, where the thin mucosal tissue allows the active ingredient to absorb directly into the bloodstream through the sublingual vein and nearby capillaries.
- Advantages: Bypasses stomach acid entirely. Faster onset than oral pills. No fasting protocol needed.
- Challenges: The sublingual area is small, limiting how much drug can be absorbed per dose. Saliva production can wash the medication into the stomach before absorption is complete. Holding a liquid under your tongue for several minutes requires patience.
- GLP-1 application: Several compounding pharmacies offer sublingual semaglutide drops. Absorption rates are not standardized and may vary between formulations.
Buccal Delivery
Buccal means "between the cheek and gum." A troche (a lozenge-like dosage form) or film is placed against the cheek, where it slowly dissolves and absorbs through the buccal mucosa.
- Advantages: Larger absorption surface than sublingual. The troche can dissolve over 15–30 minutes, allowing sustained absorption. Less affected by saliva wash-out.
- Challenges: Slower absorption than sublingual. Some of the drug inevitably gets swallowed with saliva, reaching the stomach where it may be degraded.
- GLP-1 application: Compounded semaglutide troches are one of the most common non-injectable formats offered by telehealth providers. They're designed to dissolve slowly against the cheek.
Orally Disintegrating Tablets (ODT)
ODTs are tablets designed to disintegrate on the tongue within seconds. They're common in other drug classes (anti-nausea, allergy medications) and are now appearing in the compounded GLP-1 space.
- Advantages: Easy to take — no water needed, no sustained holding in the mouth. Familiar format for patients.
- Challenges: Despite disintegrating in the mouth, most of the drug from an ODT is actually swallowed and absorbed in the GI tract — it's not truly sublingual or buccal absorption. For peptides, this means the same stomach degradation problem applies unless the formulation includes a protective mechanism.
- GLP-1 application: Some compounded providers market ODT semaglutide or tirzepatide. The absorption pathway depends on the specific formulation.
How These Compare
| Format | Absorption Route | Stomach Bypass? | Fasting Needed? | FDA-Approved GLP-1? |
|---|---|---|---|---|
| Standard pill (SNAC) | Stomach lining | No — absorbs IN stomach | Yes (30 min) | Yes |
| Sublingual drops | Under tongue → bloodstream | Mostly yes | No | No |
| Buccal troche | Cheek mucosa → bloodstream | Partially | No | No |
| ODT | Mixed (mouth + GI) | Partially | Varies | No |
| Injectable | Subcutaneous → bloodstream | Completely | No | Yes |
The Evidence Gap
There are no published Phase 3 clinical trials on sublingual, buccal, or ODT semaglutide or tirzepatide. The bioavailability of these formats — how much active drug actually reaches your bloodstream — is not publicly established with the same rigor as FDA-approved products. Providers who offer these formats report clinical outcomes in their patient populations, but that's different from controlled trial data.
This doesn't mean these formats don't work — patients report weight loss, and providers wouldn't continue offering them without seeing clinical results. But the level of evidence is meaningfully different from what supports oral Wegovy or Foundayo.
Compounded Oral Options Available Now
MadeMed
Oral SemaglutideCompounded oral semaglutide in tablet form. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
MadeMed
Oral TirzepatideCompounded oral tirzepatide tablets. Quarterly plan brings cost to $89/month; monthly refill is $119/month.
Sublingual, buccal, and ODT formats represent creative pharmacological approaches to delivering GLP-1 peptides without needles. They bypass the stomach-acid problem to varying degrees, but none have the clinical trial validation that FDA-approved products carry. If you choose a compounded oral GLP-1, understanding which absorption pathway your specific product uses helps you set realistic expectations and use it correctly.
This article is for educational purposes. Compounded medications are not FDA-approved. Consult a licensed healthcare provider before starting any GLP-1 treatment.